24 Miss. Code. R. 2-53.11 - Requirements Office Based Opioid Treatment (OBOT) Providers
A. Office Based Opioid Treatment (OBOT)
Services must meet the following requirements:
1. Individualized, patient-centered
assessment and treatment.
2.
Assessing, ordering, administering, reassessing, and regulating medication and
dose levels appropriate to the person; supervising withdrawal management from
opioid analgesics; overseeing and facilitating access to appropriate treatment
for OUD and other substance use disorders (SUD).
3. Buprenorphine mono product shall only be
prescribed to pregnant women.
4.
Maximum daily buprenorphine/naloxone dose of 16 mg unless there is
documentation of an ongoing compelling clinical rationale for a higher
maintenance dose up to maximum of 24 mg.
5. Programs should require all persons to be
benzodiazepine free after 90 days of admission unless strict monitoring is
taking place by a licensed professional and treatment team.
6. Medication for other physical and mental
health disorders is provided as needed either on-site or through collaboration
with or referral to other providers.
7. Cognitive, behavioral, and other
SUD-focused therapies, reflecting a variety of treatment approaches, provided
to the patient on an individual, group, and/or family basis.
8. Care coordination provided including
interdisciplinary care planning between buprenorphine-waivered practitioner and
the licensed behavioral health provider to develop and monitor individualized
and personalized treatment plans that are focused on the best outcomes for the
patient, monitoring patient progress and tracking patient outcomes, linking
patients with community resources (including recovery support services) to
facilitate referrals and respond to social service needs, and tracking and
supporting patients when they obtain medical, behavioral health, or social
services outside the practice.
9.
Provision of or referral for screening for HIV, Hepatitis B and C, and
Tuberculosis (TB) at treatment initiation and then annually. Risk management
and adherence monitoring if they test positive.
10. Routine and/or random urine drug screens
conducted a minimum of eight (8) times per year for all patients with at least
some tests unannounced or random.
11. Mississippi Prescription Monitoring
Program checked at least quarterly for all patients.
12. Opioid overdose prevention education
including the prescribing of naloxone for all patients.
13. Patients seen at least weekly during the
first month when initiating treatment. Patient must have been seen for at least
three (3) months with documented clinical stability before spacing out to a
minimum of monthly visits with buprenorphine-waivered practitioner or licensed
behavioral health provider.
14.
Periodic monitoring of unused medication and opened medication wrapper counts
when clinically indicated.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.